Literature DB >> 10584895

Incidence of Lyme borreliosis in the Würzburg region of Germany.

H I Huppertz1, M Böhme, S M Standaert, H Karch, S A Plotkin.   

Abstract

To assess the incidence of Lyme borreliosis in Central Europe, a 12-month, prospective, population-based surveillance study of Lyme borreliosis was conducted in the Wurzburg region of central Germany, following an aggressive awareness campaign. The diagnosis of Lyme borreliosis required the presence of (i) erythema migrans (diameter > or =5 cm); (ii) lymphocytoma; or (iii) another specific manifestation including Lyme arthritis, neuroborreliosis, carditis or acrodermatitis chronica atrophicans in conjunction with serological confirmation. A total of 313 cases of Lyme borreliosis was diagnosed, giving an incidence of 111 cases/100000 inhabitants, the highest rates occurring in children and elderly adults living in wooded as opposed to agricultural areas. The incidence in city dwellers and inhabitants of rural areas was not significantly different. Erythema migrans was the only manifestation in 279 (89%) patients. Of the 34 patients with manifestations other than erythema migrans alone, 15 had arthritis, nine neuroborreliosis, six lymphocytoma, four acrodermatitis chronica atrophicans and one carditis. Children were more likely than adults to have manifestations other than erythema migrans alone. Lyme borreliosis was very common in central Germany, and one of the most frequent bacterial infections. The observation of more cases of arthritis than neuroborreliosis was similar to that in the USA. These results may be representative for many parts of central Europe and suggest the need for development of a vaccine against borreliosis caused by European strains of Borrelia species.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584895     DOI: 10.1007/s100960050381

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  52 in total

1.  [Ambiguous swelling of the earlobe].

Authors:  A Knopf; K Becker; C Rasch
Journal:  HNO       Date:  2010-07       Impact factor: 1.284

Review 2.  Antibiotic treatment of Lyme borreliosis: what is the evidence?

Authors:  R Dinser; M C Jendro; S Schnarr; H Zeidler
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

3.  [Papilledema and thought disorder].

Authors:  S Waibel; L E Pillunat; E Matthé
Journal:  Ophthalmologe       Date:  2019-10       Impact factor: 1.059

Review 4.  [Bacterial infections of the central nervous system].

Authors:  M Klein; H-W Pfister
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

Review 5.  Lyme disease--current state of knowledge.

Authors:  Roland Nau; Hans-Jürgen Christen; Helmut Eiffert
Journal:  Dtsch Arztebl Int       Date:  2009-01-30       Impact factor: 5.594

Review 6.  [Neuroborreliosis - Diagnostics, treatment and course].

Authors:  R Dersch; S Rauer
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

7.  [Lyme borreliosis].

Authors:  P Herzer; V Fingerle; H-W Pfister; A Krause
Journal:  Internist (Berl)       Date:  2014-07       Impact factor: 0.743

8.  Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life.

Authors:  Tobias Back; Steffi Grünig; Yaroslav Winter; Ulf Bodechtel; Kersten Guthke; Diana Khati; Rüdiger von Kummer
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

9.  Mimicry of lyme arthritis by synovial hemangioma.

Authors:  Toni Hospach; M Langendörfer; T V Kalle; F Tewald; T Wirth; G E Dannecker
Journal:  Rheumatol Int       Date:  2009-12-16       Impact factor: 2.631

Review 10.  Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis.

Authors:  Gabriel Torbahn; Heidelore Hofmann; Gerta Rücker; Karin Bischoff; Michael H Freitag; Rick Dersch; Volker Fingerle; Edith Motschall; Joerg J Meerpohl; Christine Schmucker
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.